Sign In
to Vote &
Create Storyboards.
 
Data from the real-world XAMOS study just published in the journal Thrombosis and Haemostasis reaffirms the benefits of oral, once-daily Xarelto® (rivaroxaban) in everyday clinical practice to prevent potentially deadly blood clots in adults following major orthopaedic surgery of the hip or knee. Outcomes from the 17,000-patient study show Xarelto provided a favourable benefit-risk profile with patients experiencing fewer thromboembolic events and comparable low major bleeds compared to convent...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard